Invitrogen introduced the GIBCO OpTmizer T-cell Expansion SFM, a next-generation solution for culturing and expanding human T-cells that does not require the addition of serum to achieve optimal, cost-efficient results. OpTmizer SFM will enable scientists to advance their research on the central role that T-cells play in human immune response.
Invitrogen formulated the OpTmizer SFM to enable superior cell growth and viability with consistent results, without the addition of serum. It achieves superior performance criteria for growth, viability and cell yield under serum-free conditions, compared to all other commercial T-cell media, according to the company. This is an improvement over other products on the market for T-cell culture and expansion, which are limited in their performance without the addition of human serum to feed the cells.
OpTmizer SFM is also xeno-free; it does not contain material of non-human origin. It is available in Research Use Only grade. This product is manufactured under cGMP regulations, and comes with an FDA Drug Master File to support regulatory filings.